ArticleFrontiers in oncology2026
Acute hypersensitivity reactions to paclitaxel polymeric micelles during malignant tumor treatment: a retrospective real-world study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Paclitaxel polymeric micelles (pm-Pac) are widely used for solid tumors, but real-world data on acute hypersensitivity reactions (HSRs) are limited. This exploratory study aimed to characterize the clinical features, risk factors, and dynamic laboratory changes in pm-Pac-associated acute HSRs. Methods: This retrospective study included 220 patients treated with pm-Pac from March 2023 to April 2026. Clinical data were extracted from electronic medical records. Analyses included chi-square tests, linear-by-linear association, logistic regression, and linear mixed-effects models. Results: The overall HSR incidence was 6.8% (15/220). Most HSRs were mild-to-moderate (grade 1: 40.0%; grade 2: 33.3%) and 26.7% were grade 3. Reactions occurred predominantly within the first 60 minutes (60.0%); 88.9% of moderate-to-severe reactions (grade ≥2) occurred within this window. Fourteen events (93.3%) occurred during the second cycle, and one (6.7%) during the third cycle, with no recurrence in six patients who continued treatment. Rash and pruritus were most common manifestations, followed by cardiovascular symptoms. Conventional risk factors showed no significant associations, and routine laboratory parameters were similar between groups. Baseline autoantibody positivity was 66.7% in HSR compared with 41.2% in non-HSR patients ( Conclusions: Pm-Pac-induced acute HSRs were predominantly mild-to-moderate cutaneous reactions, occurring within the first 60 minutes and during the second cycle; grade ≥2 reactions were more frequent in the early time window. No recurrent reactions were observed in subsequent cycles. Routine laboratory monitoring did not differentiate between patients with and without HSRs; symptom surveillance is essential. Baseline autoantibody positivity showed a non-significant trend that requires validation. Given the small sample (n=15), all findings are exploratory and require confirmation in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.